Cover Image

Comparative efficacy of talquetamab vs. current treatments in the LocoMMotion and MoMMent studies in patients with triple-class-exposed relapsed/refractory multiple myeloma

Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-wor...

Full description

Saved in:
Bibliographic Details
Main Authors: Einsele, Hermann (Author) , Moreau, Philippe (Author) , Bahlis, Nizar (Author) , Bhutani, Manisha (Author) , Vincent, Laure (Author) , Karlin, Lionel (Author) , Perrot, Aurore (Author) , Goldschmidt, Hartmut (Author) , van de Donk, Niels W. C. J. (Author) , Ocio, Enrique M. (Author) , Martinez-Lopez, Joaquin (Author) , Rodríguez-Otero, Paula (Author) , Dytfeld, Dominik (Author) , Diels, Joris (Author) , Strulev, Vadim (Author) , Haddad, Imene (Author) , Renaud, Thomas (Author) , Ammann, Eric (Author) , Cabrieto, Jedelyn (Author) , Perualila, Nolen (Author) , Gan, Ryan (Author) , Zhang, Youyi (Author) , Parekh, Trilok (Author) , Albrecht, Claire (Author) , Weisel, Katja (Author) , Mateos, Maria-Victoria (Author)
Format: Article (Journal)
Language:English
Published: 24 February 2024
In: Advances in therapy
Year: 2024, Volume: 41, Issue: 4, Pages: 1576-1593
ISSN:1865-8652
DOI:10.1007/s12325-024-02797-x
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1007/s12325-024-02797-x
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s12325-024-02797-x
Get full text
Author Notes:Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W. C. J. van de Donk, Enrique M. Ocio, Joaquin Martinez-Lopez, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imene Haddad, Thomas Renaud, Eric Ammann, Jedelyn Cabrieto, Nolen Perualila, Ryan Gan, Youyi Zhang, Trilok Parekh, Claire Albrecht, Katja Weisel, Maria-Victoria Mateos
Description
Summary:Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician’s choice of therapy (RWPC) was assessed using adjusted comparisons.
Item Description:Gesehen am 10.09.2024
Physical Description:Online Resource
ISSN:1865-8652
DOI:10.1007/s12325-024-02797-x

Similar Items